Leaders from the Guangxi Institute for Food and Drug Control visit Baihui Pharmaceutical for technical exchange.

Release date:

2021-07-16

On the morning of July 15, 2021, upholding the principles of strengthening technical exchanges, deepening collaborative integration, and serving enterprises, Gan Yongqiang, Deputy Director of Guangxi Institute for Food and Drug Control; Lu Rigang, Director of the Chemical Pharmaceutical Department; Gan Yongqi, Deputy Director of the Microbiology Department, and other leaders visited Baihui Pharmaceutical. There, they engaged in technical discussions and provided guidance alongside Guo Xiong, General Manager of Baihui Pharmaceutical; Deng Haichao, Deputy General Manager; Zhou Jian, the company’s head; Lin Qiaohui, Director of Quality, and other key personnel.

On the morning of July 15, 2021, upholding the principles of strengthening technical exchanges, deepening collaborative integration, and serving enterprises, Gan Yongqiang, Deputy Director of the Guangxi Institute for Food and Drug Control; Lu Rigang, Director of the Chemical Drug Department; Gan Yongqi, Deputy Director of the Microbiology Department, and other leaders visited Baihui Pharmaceutical. There, they engaged in technical discussions and provided guidance alongside Guo Xiong, General Manager of Baihui Pharmaceutical; Deng Haichao, Deputy General Manager; Zhou Jian, the company’s head; Lin Qiaohui, Quality Director, and other key personnel.

Gan Yongqiang and his delegation first visited the Baohui Pharmaceutical exhibition hall, where they learned in detail about the company’s history, culture, and product manufacturing processes. Following the tour, both sides held a symposium. Guo Xiong, General Manager of Baohui Pharmaceutical, began by providing an overview of the company’s current status, including its business performance in the first half of the year, as well as its future development plans.

Deputy Director Gan Yongqiang stated that, with the development of the market economy, the Drug Testing Institute is not only strengthening its supervision and inspection of drug quality but also fully leveraging its technical expertise in pharmaceutical regulation. By capitalizing on the institute's technological strengths, it is implementing effective measures to enhance support for pharmaceutical manufacturers, promptly gathering insights into companies' growth trends and addressing their most pressing technical challenges. This proactive approach helps resolve enterprises' concerns, ultimately fostering faster and higher-quality development within the pharmaceutical industry.